iRhythm Holdings finalizes the acquisition of VitalConnect, bolstering its cardiac monitoring portfolio with new wearable biosensor technology to capture broader market segments.
iRhythm has successfully finalized the acquisition of VitalConnect, a strategic move designed to bolster its leadership in the wearable biosensor and ambulatory cardiac monitoring market. By integrating VitalConnect's technology, iRhythm aims to broaden its service offerings across the entire continuum of care, spanning from hospital settings to home-based monitoring.
It allows iRhythm to expand its cardiac monitoring platform beyond ambulatory care into inpatient and hospital-to-home settings.
VitalConnect has been fully acquired by iRhythm, marking a successful exit for the company's stakeholders. The acquisition serves to fold VitalConnect's specialized wearable biosensor technology into iRhythm's broader infrastructure, effectively ending its status as an independent entity.
No, VitalConnect has been acquired by iRhythm Holdings, Inc. and is now part of their corporate structure.
iRhythm Holdings has finalized its acquisition of VitalConnect, integrating advanced wearable biosensor technology into its existing cardiac monitoring platform. This strategic move strengthens the company's service capabilities across ambulatory, inpatient, and hospital-to-home care settings.
The acquisition allows iRhythm to incorporate VitalConnect's wearable biosensor technology, enabling a more comprehensive cardiac monitoring platform that spans from hospital settings to home care.